Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Nov 1;33(6):472-481.
doi: 10.1097/MOU.0000000000001132. Epub 2023 Sep 25.

Prognostic impact of serum testosterone in metastatic hormone-naive prostate cancer: a systematic review and meta-analysis

Ignacio Puche-Sanz  1 , Peter Chiu  2 , Ana C Morillo  3 , Enrique Gomez-Gomez  3 ; On behalf of the BATEMARK-YAU-21 Study Group
Affiliations
Meta-Analysis

Prognostic impact of serum testosterone in metastatic hormone-naive prostate cancer: a systematic review and meta-analysis

Ignacio Puche-Sanz et al. Curr Opin Urol. .

Abstract

Purpose of review: In daily practice, there is an unmet medical need for biomarkers that facilitate therapeutic decision-making in the metastatic hormone sensitive prostate cancer (mHSPC) scenario. Although recent studies have highlighted the potential of testosterone as a prognostic and predictive marker in prostate cancer, the evidence is controversial. The objective of this review was to summarize and analyze the scientific evidence regarding the prognostic role of basal testosterone levels in patients with mHSPC.

Methods: A systematic review was performed. Three authors selected the articles from Web of Science, PubMed, Scopus, and Cochrane Library electronic databases. Risk of bias was assessed by the Newcastle Ottawa Scale.

Recent findings: Most of the selected articles suggest that low testosterone levels before starting hormonal blockade imply a worse prognosis for patients with mHSPC. However, the quality of the evidence is poor, the studies are heterogeneous, and it is not possible to meta-analyze most of the published results.

Summary: Testosterone is an accessible and affordable biomarker. If it were correctly demonstrated that it harbors a prognostic and/or predictive role in the mHSPC setting, it could represent an advance in decision-making in these patients. Well designed prospective studies are needed to correctly answer this question.

PubMed Disclaimer

References

    1. Varenhorst E, Klaff R, Berglund A, et al. Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases. Cancer Med 2016; 5:407–414.
    1. Sumanasuriya S, Omlin A, Armstrong A, et al. Consensus statement on circulating biomarkers for advanced prostate cancer. Eur Urol Oncol 2018; 1:151–159.
    1. Klap J, Schmid M, Loughlin KR. The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy. J Urol 2015; 193:403–414.
    1. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med 2021; 18:e1003583.
    1. Peterson J, Welch V, Losos, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute. 2011. Available at: www.ohri.c:1--12 .